Stock Analiz

HCW Biologics Inc. HCWB

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$0.77Market cap $2M
Open the interactive analysis →

HCW Biologics Inc. (HCWB) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to June 30, 2026 it had revenue of $7M and net income of -$6M, a net margin of -83.0%.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -58% a year, a 5-year average ROIC of -1032%.

About HCW Biologics

HCW Biologics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $4M in 2020 to $54232 in 2025, a decline of about 57.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 134% over three years (dilution for shareholders). It spends 10036% of revenue on research and development.

Score: 0.2 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.3
P/B0.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-774.6%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-97.9%
Revenue growth (5 yrs, per year)-57.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4237.0%
ROIC (5-yr avg.)-1032.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$7M$54232$3M$3M$7M$0$4M
Net income-$6M-$8M-$30M-$25M-$15M-$13M-$6M
Free cash flow—-$13M-$14M-$29M-$21M-$11M-$11M
EPS (diluted)$-2.66$-10.63$-30.96$-28.00$-16.80$-27.60$-59.60
Net margin-83.0%-14677.1%-1169.7%-879.5%-221.7%—-141.5%
ROIC—-137.5%-4847.3%-129.9%-19.9%-26.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does HCW Biologics pay a dividend?

Not currently.

Is HCW Biologics a good stock to buy?

We do not give buy or sell advice. HCW Biologics scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.